Histone deacetylase 10 promotes autophagy-mediated cell survival

Autor/innen

  • I. Oehme
  • J.P. Linke
  • B.C. Böck
  • T. Milde
  • M. Lodrini
  • B. Hartenstein
  • I. Wiegand
  • C. Eckert
  • W. Roth
  • M. Kool
  • S. Kaden
  • H.J. Gröne
  • J.H. Schulte
  • S. Lindner
  • A. Hamacher-Brady
  • N.R. Brady
  • H.E. Deubzer
  • O. Witt

Journal

  • Proceedings of the National Academy of Sciences of the United States of America

Quellenangabe

  • Proc Natl Acad Sci U S A 110 (28): E2592-E2601

Zusammenfassung

  • Tumor cells activate autophagy in response to chemotherapy-induced DNA damage as a survival program to cope with metabolic stress. Here, we provide in vitro and in vivo evidence that histone deacetylase (HDAC)10 promotes autophagy-mediated survival in neuroblastoma cells. We show that both knockdown and inhibition of HDAC10 effectively disrupted autophagy associated with sensitization to cytotoxic drug treatment in a panel of highly malignant V-MYC myelocytomatosis viral-related oncogene, neuroblastoma derived-amplified neuroblastoma cell lines, in contrast to nontransformed cells. HDAC10 depletion in neuroblastoma cells interrupted autophagic flux and induced accumulation of autophagosomes, lysosomes, and a prominent substrate of the autophagic degradation pathway, p62/sequestosome 1. Enforced HDAC10 expression protected neuroblastoma cells against doxorubicin treatment through interaction with heat shock protein 70 family proteins, causing their deacetylation. Conversely, heat shock protein 70/heat shock cognate 70 was acetylated in HDAC10-depleted cells. HDAC10 expression levels in high-risk neuroblastomas correlated with autophagy in gene-set analysis and predicted treatment success in patients with advanced stage 4 neuroblastomas. Our results demonstrate that HDAC10 protects cancer cells from cytotoxic agents by mediating autophagy and identify this HDAC isozyme as a druggable regulator of advanced-stage tumor cell survival. Moreover, these results propose a promising way to considerably improve treatment response in the neuroblastoma patient subgroup with the poorest outcome.


DOI

doi:10.1073/pnas.1300113110